Underestimated Disease Prevalence and Severe Phenotypes in Patients with Biallelic Variants: A Cohort Study of Primary Familial Brain Calcification from China
Si Chen,Zhidong Cen,Feng Fu,You Chen,Xinhui Chen,Dehao Yang,Haotian Wang,Hongwei Wu,Xiaosheng Zheng,Fei Xie,Zhiyuan Ouyang,Weiguo Tang,Shuhong Zhang,Lili Yin,Yunqian Zhang,Peiying Meng,Xuzhen Zhu,Hongwei Zhang,Feifei Jiang,Kaiyu Zhang,Juping He,Danhong Zhang,Hanqiao Ming,Daqiao Song,Zhiping Zho,Yong Luo,Qun Gu,Yongkun Su,Xinxiao Wu,Haiyan Tang,Chenglong Wu,Weiqing Chen,Jing-Yu Liu,Wei Luo,Xuerong Huang,Shaowei Fu,Wenhai Chen,Yanbin Huang,Likang Lan,Xiaofen Zhu,Zhijun Xu,Huayun Huang,Lifeng Zhou,Zilong Chen,Minfang Lou,Binglan Wang,Yi Tan,Manlian Zhu,Weijun Hong,Feng Wang,Gonghua Pan,Aimin Shao,Weiying Li,Haijun Li,Na Zhao,Haoyu Hu,Yaxi Zhang,Mengjia Lian,Jieying Li,Xueli Cai,Zixian Luo,Yan Zhou,Xiaoyi Lu,Li Ma,Enkui Xia,Xiaoluo Zhang
DOI: https://doi.org/10.1016/j.parkreldis.2019.04.009
IF: 4.402
2019-01-01
Parkinsonism & Related Disorders
Abstract:Background: Primary familial brain calcification (PFBC) is a rare calcifying disorder of the brain with extensive clinical and genetic heterogeneity. Its prevalence is underestimated due to clinical selection bias (compared with symptomatic PFBC patients, asymptomatic ones are less likely to undergo genetic testing). Methods: A total of 273 PFBC probands were enrolled in a multicenter retrospective cohort study by two different approaches. In Group I (nonsystematic approach), 37 probands diagnosed at our clinic were enrolled. In Group II (systematic approach), 236 probands were enrolled by searching the medical imaging databases of 50 other hospitals using specific keywords. Genetic testing of four genes known to be causative of autosomal dominant PFBC was performed in all probands using cDNA. All identified variants were further confirmed using genomic DNA and classified according to ACMG-AMP recommendations. Results: Thirty-two variants including 22 novel variants were detected in 37 probands. Among these probands, 83.8% (31/37) were asymptomatic. Two probands with homozygous pathogenic SLC20A2 variants presented more severe brain calcification and symptoms. Based on the variant detection rate of probands in Group II, we extrapolated an overall minimal prevalence of PFBC of 6.6 per 1,000, much higher than previously reported (2.1 per 1000). Conclusions: We identified a higher proportion of genetically confirmed PFBC probands who were asymptomatic. These patients would be overlooked due to clinical selection bias, leading to underestimation of the disease prevalence. Considering that PFBC patients with biallelic variants had more severe phenotypes, this specific condition should be focused on in genetic counseling.